Product image of Linagliptina Sandoz (Linagliptin) supplied by GNH India

Linagliptina Sandoz

Active Ingredient:
Linagliptin
Origin:
EU

Linagliptina Sandoz (Linagliptin)

Linagliptin, the active ingredient in Linagliptina Sandoz, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral administration. It is used to improve glycaemic control in adults with type 2 diabetes mellitus, often as part of a comprehensive diabetes management plan that includes diet and exercise.

GNH India supplies Linagliptina Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing and consistent product quality.

Manufacturer / TM Owner

Sandoz Farmaceutica Lda.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Linagliptina Sandoz is a DPP‑4 inhibitor indicated for the management of type 2 diabetes mellitus.

  • Type 2 diabetes mellitus (monotherapy): lowers blood glucose when used alone.
  • Type 2 diabetes mellitus (combination therapy): enhances glycaemic control when added to metformin, sulfonylureas or insulin.
  • Type 2 diabetes mellitus (adjunct to diet and exercise): helps achieve target HbA1c as part of lifestyle modification.

How It Works

  • Linagliptin selectively inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, which degrades the incretin hormones GLP‑1 and GIP. By preventing this degradation, linagliptin increases circulating incretin levels, leading to glucose‑dependent stimulation of insulin secretion and suppression of glucagon release, thereby improving post‑prandial and fasting blood glucose concentrations.

Side Effects

Common side effects are generally mild and may resolve without intervention.

Common Side Effects

  • Nasopharyngitis: inflammation of the nasal passages and throat.
  • Headache: mild to moderate intensity.
  • Upper respiratory tract infection: symptoms of cough and congestion.
  • Dizziness: transient sensation of light‑headedness.
  • Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain requiring immediate medical attention.
  • Severe allergic reactions: rash, swelling, or anaphylaxis.
  • Hepatic injury: elevated liver enzymes or jaundice.
  • Hypoglycaemia: especially when combined with insulin or sulfonylureas.
  • Bullous pemphigoid: rare skin disorder with blistering lesions.

Precautions & Warnings

Linagliptina Sandoz should be used with careful clinical assessment and monitoring.

  • Renal impairment: monitor renal function regularly.
  • Hepatic impairment: use with caution in patients with liver disease.
  • Hypersensitivity: discontinue if signs of allergic reaction appear.
  • Pregnancy: risk unknown; avoid unless clearly needed.
  • Drug interactions: review concomitant medications for potential interactions.
  • Store at ambient temperature: keep in the original container, protect from moisture.

Avoid Interactions

Linagliptina Sandoz may interact with several drug classes; assessment of the interaction risk is essential.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase linagliptin exposure.
  • Combination with insulin or sulfonylureas: heightened risk of hypoglycaemia.

Moderate Interactions (Monitor Closely)

  • Rifampin: may reduce linagliptin effectiveness.
  • Diuretics: may affect glucose control.
  • ACE inhibitors: monitor renal function and potassium levels.
  • NSAIDs: watch for potential renal effects.
  • Anticoagulants: observe for any changes in bleeding risk.

Frequently Asked Questions

Linagliptina Sandoz contains linagliptin, a DPP‑4 inhibitor indicated for the treatment of type 2 diabetes mellitus in adults. It helps lower blood glucose levels when used alone or in combination with other antidiabetic agents as part of a comprehensive diabetes management plan.

Linagliptin works by selectively inhibiting the DPP‑4 enzyme, which normally breaks down the incretin hormones GLP‑1 and GIP. By preserving these hormones, linagliptin enhances glucose‑dependent insulin secretion and reduces glucagon release, leading to improved blood‑sugar control.

The appropriate dose of Linagliptina Sandoz is determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for linagliptin in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Linagliptin is a once‑daily DPP‑4 inhibitor that does not require dose adjustment in mild to moderate renal impairment, unlike some other agents in the class. Its efficacy in lowering HbA1c is comparable, while its safety profile is similar, with a low incidence of hypoglycaemia when used as monotherapy.

Linagliptina Sandoz should be stored at ambient temperature, below 25 °C, in the original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date.

The medication is taken orally, usually once daily, with or without food. Patients should swallow the tablet whole with a glass of water and follow the dosing schedule prescribed by their healthcare professional.

Serious risks, although rare, include pancreatitis, severe allergic reactions such as anaphylaxis, and hepatic injury. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, swelling, or signs of liver dysfunction.

Linagliptina Sandoz should be avoided in individuals with a known hypersensitivity to linagliptin or any excipients in the formulation. Caution is also advised for patients with severe hepatic impairment, and it is not recommended for use in pregnancy unless clearly indicated by a physician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Linagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT